Recently, Schwartz and colleagues [30] explained the epitope for any related b96 antibody produced after cloning of the b96 cell line. but two APS2 IgG antibodies require this region and amino acids 529C570. In contrast, the binding of MICA-3 requires two discontinuous amino acid segments of GAD65 (452C513 and 528C569), but not amino acids 514C528. These results indicate that there are both similarities and differences in the humoral response to GAD65 in APS2 and IDDM. Keywords: diabetes, epitope, monoclonal antibody, glutamic acid decarboxylase INTRODUCTION Autoantibodies to GAD are an important marker for type 1 diabetes or insulin-dependent diabetes mellitus (IDDM) [1C8]. Individuals with other autoimmune diseases such as stiff man syndrome (SMS) Calyculin A and autoimmune polyglandular failure syndromes (APS) also have autoantibodies to GAD [9C17]. Diabetes is often a component of SMS and autoimmune polyendocrine syndrome type 2 (APS2), whereas it is not a usual feature of APS1 [18]. While there is an autoimmune response to GAD65 in all three diseases, a difference in the clinical frequency of diabetes suggests that the autoimmunity to GAD may differ in these diseases. GAD65 autoantibodies in SMS have both similarities to and differences with those found in IDDM [12,14C16,19]. For example, SMS sera contain an antibody which targets a linear epitope in the amino-terminus of Calyculin A GAD65, while this type of antibody is not present in IDDM sera [12C15]. GAD autoantibodies in APS1 and SMS also inhibit the enzymatic activity of GAD65, while this is not a property of IDDM autoantibodies [9,19]. Since GAD autoantibodies in IDDM bind conformation-dependent epitopes, chimeric proteins of GAD65 and GAD67 have been utilized to maintain protein conformation and allow identification of targeted regions of GAD65 [20]. GAD autoantibodies in IDDM serum target regions in the middle and carboxy-terminus of GAD65 ([20]; termed IDDM-E1 and IDDM-E2), but whether comparable epitopes are targeted in polyglandular autoimmune syndromes is not known. A recent report suggested that GAD autoantibodies in polyglandular autoimmune syndromes are heterogeneous [21]. Definition of the epitopes targeted in IDDM and polyglandular syndromes Calyculin A has been assisted by panels of MoAbs derived from individuals with the disease [22C24], but the precise regions targeted by these MoAbs remain incompletely defined. The purpose of the current study was to determine and compare GAD65 epitopes targeted in autoimmune polyglandular failure syndromes and IDDM using MoAbs derived from an individual with IDDM and an individual with APS2. MATERIALS AND METHODS Serum and antibody samples The isolation of human MoAbs, MICA-2, MICA-3 and MICA-4, has been previously explained [23]. The isolation of human IgG antibodies from your lines b35, b78, and b96, from an APS2-like patient, has been previously explained [24]. Supernates of tissue culture media Calyculin A made up of the IgG antibodies or MoAbs were diluted so as to immunoprecipitate approximately the same amount of labelled GAD65 or chimeric GAD protein. Immunoprecipitation of GAD protein The binding by MoAbs was assayed in duplicate using a binding assay as Leuprorelin Acetate previously explained [20]. The specificity of this GAD assay has been confirmed by the participation Calyculin A of our laboratory in interlaboratory GAD antibody workshops [25,26]. Background or non-specific binding (binding of labelled protein to protein A-Sepharose alone) was subtracted from your binding of each MoAb. This background binding varied with each chimeric protein but was < 5C10% of the total binding. MoAbs.